Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
McKinsey
Merck
AstraZeneca
Baxter

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Litigation Details for IVAX PHARMACEUTICALS, INC. v. LEAVITT (D.C. 2005)

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in IVAX PHARMACEUTICALS, INC. v. LEAVITT
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for IVAX PHARMACEUTICALS, INC. v. LEAVITT (D.C. 2005)

Date Filed Document No. Description Snippet Link To Document
2005-11-07 1 Complaint submitted one patent to the FDA as claiming Zocor®, U.S. Patent No. 4,444,784 (the “’784 patent”). The ’784…properly delisted U.S. Patent Nos. RE 36481 (’481 patent) and RE 36520 (’520 patent) f`rom the Approved …challenged two patents that Merck had listed as claiming Zocor®, the ’481 patent and ’520 patent, entitling… ’481 patent and the ’520 patent. All three patents were listed in the Orange Book as of December 14, …the listing of the ’481 and ’520 patents from the Orange Book as patents claiming Zocor®. FDA did so prior External link to document
2005-12-02 10 *Restricted* (2), 21 CFR601.2) 13. Patent information on any patent which claims the drug (21 U.S.C. 355… of (c)) X 14. A patent certification with respect to any patent which claims the drug (21 U.S.C… Patent Certification and Exclusivity Statement Patent Certification: …the patent held by Merck& Co. will expire on the following date: ¯ U.S. Patent No. 4,444,784…: ¯ U.S. Patent RE36481-Expiry date: July 10, 2007 ¯ U.S. Patent RE36520-Expiry date External link to document
2005-11-07 5 Exhibit Memorandum in Support of Motion for Summary Judgment submitted one patent to the FDA as claiming Zocor®, U.S. Patent No. 4,444,784 (the ‘784 patent”). The ‘784…the Act)._ Th_ese include U-. S Patent- No 4 444 784 (_'784 patent_),_ which _wa__s. listed _a___t…additional patents, U.S. Patent Nos. RE 36481 (‘481 patent) and RE 36520 (‘520 patent). All three patents were…the '449 patent ~- it's actually not a GSK patent. The '449 patent is a patent that relates… the patent holder requesting to delist its patent_unless the two parties are engaged in a patent infringement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Colorcon
Moodys
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.